JL
Insider
John L Lamattina
DirectorJohn L Lamattina (Director) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales, 1 filed past the two-business-day deadline), most often in Ligand Pharmaceuticals Incorporated (LGND). The largest single filing was $1.0M of LGND (4,102 sh across 2 lots, as filed), executed Jun 10.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells · 1 late
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.3M
shares × price, as filed
Last traded
Jun 10
Filed Jun 12
Median ADV $104.4M across their filed names
Open performance→Volume by month
Buys $0
Sells $2.6M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
LGNDRecent filings
LGNDSALE
Ligand Pharmaceuticals Incorporated
View filing →
$1.0M4,102 sh across 2 lots
Exec Jun 10
Filed Jun 12 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $434K
2,161 sh × $200.76
Exec Mar 6
Filed Mar 31 · 5:30 PM ET † LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $859K
4,179 sh across 2 lots
Exec Nov 7 2025
Filed Nov 12 2025 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated View filing → $298K
2,406 sh × $123.65
Exec Nov 27 2024
Filed Dec 2 2024 · 5:30 PM ET